- Home
- OPI vs OTLK Comparison
OPI vs OTLK Comparison
Compare OPI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- OTLK
- Stock Information
- Founded
- OPI 2009
- OTLK 2010
- Country
- OPI United States
- OTLK United States
- Employees
- OPI N/A
- OTLK N/A
- Industry
- OPI Real Estate Investment Trusts
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPI Real Estate
- OTLK Health Care
- Exchange
- OPI Nasdaq
- OTLK Nasdaq
- Market Cap
- OPI N/A
- OTLK 56.3M
- IPO Year
- OPI 2009
- OTLK 2016
- Fundamental
- Price
- OPI $0.46
- OTLK $1.22
- Analyst Decision
- OPI Buy
- OTLK Strong Buy
- Analyst Count
- OPI 2
- OTLK 5
- Target Price
- OPI $4.30
- OTLK $10.20
- AVG Volume (30 Days)
- OPI 1.1M
- OTLK 362.1K
- Earning Date
- OPI 04-30-2025
- OTLK 05-14-2025
- Dividend Yield
- OPI 8.79%
- OTLK N/A
- EPS Growth
- OPI N/A
- OTLK N/A
- EPS
- OPI N/A
- OTLK N/A
- Revenue
- OPI $501,979,000.00
- OTLK N/A
- Revenue This Year
- OPI N/A
- OTLK N/A
- Revenue Next Year
- OPI N/A
- OTLK $288.46
- P/E Ratio
- OPI N/A
- OTLK N/A
- Revenue Growth
- OPI N/A
- OTLK N/A
- 52 Week Low
- OPI $0.44
- OTLK $0.87
- 52 Week High
- OPI $3.02
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- OPI 23.02
- OTLK 33.91
- Support Level
- OPI $0.48
- OTLK $1.25
- Resistance Level
- OPI $0.94
- OTLK $1.42
- Average True Range (ATR)
- OPI 0.08
- OTLK 0.11
- MACD
- OPI -0.02
- OTLK -0.01
- Stochastic Oscillator
- OPI 4.33
- OTLK 7.89
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.